Roth G A, Nickl S, Lebherz-Eichinger D, Schmidt E M, Ankersmit H J, Faybik P, Hetz H, Krenn C G
Department of Anesthesiology, General Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Transplant Proc. 2013 Jan-Feb;45(1):241-4. doi: 10.1016/j.transproceed.2012.02.047.
Lipocalin-2 (LCN-2), which is expressed in immunocytes as well as hepatocytes, is upregulated in cells under stress from infection or inflammation with increase in serum levels. We sought to investigate the relevance of LCN-2 in the setting of acute hepatic failure, particularly when addressed with the molecular adsorbent recirculating system (MARS). We measured serum LCN-2 concentrations with enzyme-linked immunosorbent assay (ELISA) in 8 patients with acute-on-chronic-liver failure (ACLF) and acute liver failure (ALF) who were treated with MARS. The controls were 14 patients with stable chronic hepatic failure (CHF). LCN-2 was determined immediately before and after the first MARS session. Baseline LCN-2 serum concentrations were significantly increased among ACLF and ALF patients as compared with CHF (P = .004 and P = .0086, respectively). There was no significant difference between the ALF and ACLF group. Moreover, serum LCN-2 levels did not change significantly during the MARS treatment. Serum LCN-2 levels, therefore, may be useful to discern acute from chronic hepatic failure and to monitor the course as well as the severity of the disease.
脂联素-2（LCN-2）在免疫细胞和肝细胞中均有表达，在受到感染或炎症应激的细胞中会随着血清水平升高而上调。我们试图研究LCN-2在急性肝衰竭情况下的相关性，特别是在采用分子吸附循环系统（MARS）治疗时。我们用酶联免疫吸附测定法（ELISA）测量了8例接受MARS治疗的急性慢性肝衰竭（ACLF）和急性肝衰竭（ALF）患者的血清LCN-2浓度。对照组为14例稳定的慢性肝衰竭（CHF）患者。在第一次MARS治疗前后即刻测定LCN-2。与CHF相比，ACLF和ALF患者的基线LCN-2血清浓度显著升高（分别为P = 0.004和P = 0.0086）。ALF组和ACLF组之间无显著差异。此外，MARS治疗期间血清LCN-2水平无显著变化。因此，血清LCN-2水平可能有助于区分急性和慢性肝衰竭，并监测疾病进程和严重程度。
